A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response

Jung, Bo‐Kyeong; Oh, Eonju; Hong, Jae‐Keun; Lee, Yunki; Парк, Ки Донг; Yun, Chae‐Ok

doi:10.1016/j.biomaterials.2017.09.009

Cited by 46 publications

(38 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in line with prior studies of multiple tumors types treated with OV that demonstrate a modulated immune response to OV administration that contributes to control of tumor growth [47][48][49][50] . However, because this immune response is also responsible for the rapid clearance of viral particles, a delay in OV elimination could improve the therapeutic efficacy of this anti-cancer treatment strategy [51][52][53][54][55] .…”

Section: Discussionsupporting

confidence: 90%

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Chastkofsky

Katagi

et al. 2020

Preprint

View full text Add to dashboard Cite

Running Title: Stem cells deliver virotherapy to DIPG. AbstractDiffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiation therapy is the standard of care treatment for DIPG, but offers only transient relief of symptoms for DIPG patients without providing significant survival benefit. Oncolytic virotherapy (OV) is an anticancer treatment that has been investigated for treating various types of brain tumors. Here, we have explored the use of mesenchymal stem cells (MSC) for OV delivery and evaluated treatment efficacy using preclinical models of DIPG. Our results show that DIPG cells and tumors exhibit robust expression of cell surface proteins that are important for OV entry, and that MSCs loaded with OV disseminate within and release OV throughout the tumor in mice bearing DIPG brainstem xenografts. When combining administration of OV-loaded MSCs with radiotherapy, mice bearing brainstem DIPG xenografts experience a significant survival benefit, relative to that conferred by either therapy alone (p<0.0001). Our results support further preclinical investigation of cell-based OV therapy with radiation for potential translation in treating DIPG patients.

show abstract

Section: Discussionsupporting

confidence: 90%

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Chastkofsky

Katagi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…40 Hydrogel scaffolds can help to prevent premature drug (PS) release, inactivation of these drugs (e.g., curcumin) 298 via interaction with plasma components, and nonspecific site accumulation in healthy tissue , thus improving their effectiveness and sensitivity for photo-action. 299 PS hydrogel formulations can be modified by attaching functional moieties, making them target specific agents by improving their pharmacokinetics, cell uptake, and targeting ability. 300,301 This opens the way for combination therapies.…”

Section: Hydrogels In Pdt and Pactmentioning

confidence: 99%

Hydrogels: soft matters in photomedicine

Khurana

Gierlich

Meindl

et al. 2019

Photochem Photobiol Sci

View full text Add to dashboard Cite

show abstract

“…Various strategies have been used to overcome this problem including using epithelial junction opener (Yumul et al, 2016), vasoactive and metalloproteinase (Kaufman, Kohlhapp, & Zloza, 2015). Antiviral immune responses against OAds and liver toxicity of the virus could limit their efficacy and shorten Ads lifespan (Jung et al, 2017). Surface modification and polymeric coating of the virus have been used to overcome these limitations (Choi et al, 2015a;Choi, Lee, Yun, & Kim, 2015b).…”

Section: Challenges and Solutionsmentioning

confidence: 99%

Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches

Goradel

Mohajel

Malekshahi

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Cancer therapy using oncolytic viruses is an emerging area, in which viruses are engineered to selectively propagate in tumor tissues without affecting healthy cells. Because of the advantages that adenoviruses (Ads) have over other viruses, they are more considered. To achieve tumor selectivity, two main modifications on Ads genome have been applied: small deletions and insertion of tissue‐ or tumor‐specific promoters. Despite oncolytic adenoviruses ability in tumor cell lysis and immune responses stimulation, to further increase their antitumor effects, genomic modifications have been carried out including insertion of checkpoint inhibitors and antigenic or immunostimulatory molecules into the adenovirus genome and combination with dendritic cells and chemotherapeutic agents. This study reviews oncolytic adenoviruses structures, their antitumor efficacy in combination with other therapeutic strategies, and finally challenges around this treatment approach.

show abstract

A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response

Cited by 46 publications

References 46 publications

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Hydrogels: soft matters in photomedicine

Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches

Contact Info

Product

Resources

About